S4 E2 The Oncology Journal Club: Chrono-Oncology, Genomic Therapy Matching + iCCA

This episode of The Oncology Journal Club dives into four pivotal studies shaping modern oncology practice. The discussion begins with the Neo-Gulp trial in high-risk intrahepatic cholangiocarcinoma, a phase 2-3 RCT showing significant improvement in event-free survival with neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalumab, though overall survival remains immature and long-term toxicities and quality of life data are still pending. Next, the MOST program’s large-scale study in Australia demonstrates that matching genomic biomarkers to therapies with prospective trial evidence (Tiers 1–3A) leads to a doubling of median overall survival (21 vs. 12 months), reinforcing the clinical utility of precision oncology when grounded in robust evidence. The Chopin study in metastatic uveal melanoma reveals a promising survival benefit with hepatic perfusion plus ipilimumab, suggesting that liver-directed therapy may overcome immunological resistance in this 'cold' tumor. Finally, the chrono-oncology study in lung cancer finds that morning administration of immunotherapy significantly improves progression-free and overall survival, with biological plausibility in circadian CD8 T-cell dynamics, prompting real-world shifts in treatment scheduling despite concerns about confounders and sex-based differences. The panel emphasizes the need for rigorous RCTs, cautious interpretation of phase 2 signals, and equitable access to genomic testing and novel therapies across diverse populations.